Prediction of small-diameter arterial fibrosis in patients with hypertension and primary chronic glomerulonephritis

Aim. To study clinical, laboratory, and morphological risk factors for small-diameter renal arterial fibrosis in patients with hypertension (HTN) and primary chronic glomerulonephritis (CGN).

Material and methods. The study included 102 patients with primary CGN. The first group consisted of 62 patients with small-diameter renal arterial fibrosis according to renal biopsy; the second group included 40 patients without vascular fibrosis. All patients signed informed consent.

Results. A comparative analysis revealed the most significant differences between groups 1 and 2: mean systolic blood pressure (SBP)  — 131,85±17,56 mm Hg and 119,65±22,2 mm Hg, respectively (p=0,0008); mean diastolic blood pressure (DBP) — 84,11±10,7 and 79,63±9,7 mm Hg (p=0,03), respectively; peak SBP — 158,61±23,76 mm Hg and 144,25±23,56 mm Hg (p=0,002), respectively; peak DBP  — 95,66±10,33 mm Hg and 90,63±10,74 mm Hg (p=0,02), respectively; HTN stage — 1,85 [1; 3] and 1,38 [1; 3] (p=0,03), respectively; HTN grade  — 1,73 [1; 3] and 1,13 [1; 3] (p=0,004), respectively; left ventricular hypertrophy  — 15 patients and 2 patients (p=0,006), respectively; blood urea nitrogen  — 8,98±7,31 and 6,42±4,02 mmol/L (p=0,03), respectively. Significant morphological differences between first and second groups were as follows: tubulointerstitial fibrosis — 56% and 21% (p<0,001), respectively; tubulointerstitial inflamemation — 44% and 16% (p=0,002), respectively; interstitial fibrosis — 24,9±20,5% and 9,89±19,8% (p=0,001), respectively.

Conclusion. The presented analysis emphasizes a significant contribution of hemodynamics in small-diameter renal arterial fibrosis in patients with HTN and CGN. It manifested by a persistent increase of SBP and involvement of target organs. Systemic hemodynamic changes are fundamental in the development of small-diameter renal arterial fibrosis in patients with HTN and primary CGN, while the isolated progression of CGN does not significantly affect the structure of small-diameter renal arteries.

1. Kumar P, Clark M. Kumar and Clark’s Clinical Medicine. In: Elsevier Inc., 9th ed. England, 2017:734-35. ISBN 978-0-7020-6601-6.

2. Xie Y, Bowe B, Mocdad A, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94 (3):567-81. doi:10.1016/j.kint.2018.04.011.

3. Batyushin MM, Dmitrieva OV, Terentyev VP, Davydenko KS. Computational methods for predicting the risk of analgesic interstitial kidney damage. Therapeutic archive. 2008;80(6):62-5. (In Russ.)

4. Neovius M, Jacobson SH, Eriksson JK, et al. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ Open. 2014;4(2):e004251. doi:10.1136/bmjopen-2013-004251.

5. Gómez de la Torre-del Carpioa A, Bocanegra-Jesúsa A, Guinetti-Ortiza K, et al. Early mortality in patients with chronic kidney disease who started emergency haemodialysis in a Peruvian population: Incidence and risk factors. Nefrologia. 2018;38(4):347-58. doi:10.1016/j.nefroe.2018.06.005.

6. Ortiz A, Sanchez-Niño MD, Crespo-Barrio M, et al. The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. Nefrologia. 2019;39(1):29-34. doi:10.1016/j.nefroe.2019.01.007.

7. Eirin A, Lerman LO. Darkness at the End of the Tunnel: Poststenotic Kidney Injury. Physiology (Bethesda). 2013;28(4):245-53. doi:10.1152/physiol.00010.2013.

8. Hanamura K, Tojo A, Kinugasa S, et al. The Resistive Index Is a Marker of Renal Function, Pathology, Prognosis, and Responsiveness to Steroid Therapy in Chronic Kidney Disease Patients. Int J Nephrol. 2012;2012:139565. doi:10.1155/2012/139565.

9. Chade AR, Williams ML, Engel J, et al. A translational model of chronic kidney disease in swine. Am J Physiol Renal Physiol. 2018;315(2):364-73. doi:10.1152/ajprenal.00063.2018.

10. Trisvetova EL. Vascular protection in arterial hypertension — step to reduce the risk of cardiovascular complications. Medical news. 2017;11:3-4. (In Russ.)

11. Harvey A, Montezano AC, Lopes RA, et al. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32:659-68. doi:10.1016/j.cjca.2016.02.070.

12. Selvin E, Najjar SS, Cornish TC, et al. A comprehensive histopathological evaluation of vascular medial fibrosis: insights into the pathophysiology of arterial stiffening. Atherosclerosis. 2010;208:69-74. doi:10.1016/j.atherosclerosis.2009.06.025.

13. Ehling J, Babickova J, Gremse F, et al. Quantitative micro-computed tomography imaging of vascular dysfunction in progressive kidney diseases. Journal of the American Society of Nephrology. 2016;27(2):520-32. doi:10.1681/ASN.2015020204.

14. Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol. 2012;32(5):452-62. doi:10.1016/j.semnephrol.2012.07.008.

15. Afsar B, Afsar RE, Dagel T, et al. Capillary rarefaction from the kidney point of view. Clin Kidney J. 2018;11(3):295-301. doi:10.1093/ckj/sfx133.

16. Levitskaya ES, Batyushin MM, Chistyakov VA, et al. Remodeling of small-diameter kidney arteries in the prognosis of tubulointerstitial fibrosis progression in chronic glomerulonephritis. Cardiovascular Therapy and Prevention. 2019;18(3):62-8. (In Russ.) doi:10.15829/1728-8800-2019-3-62-68.